Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting

Go back to Karyopharm Presents Positive Selinexor Data from the Phase 1b/2 STOMP Study at the American Society of Hematology 2017 Annual Meeting
KARYOPHARM THERAP (NASDAQ: KPTI) Delayed: 0.42 +0.06 (16.67%)
Previous Close $0.36    52 Week High $19.41 
Open $0.36    52 Week Low $4.83 
Day High $0.44    P/E N/A 
Day Low $0.36    EPS $-2.74 
Volume 1,559,039